CMPS Latest Headlines

3 ‘Strong Buy’ Stocks to Buy Today,1/9/2026, According to Top Analysts

at www.tipranks.com (Fri, 9-Jan 9:46 AM)

De-Risked Clinical Profile and Growing Commercial Infrastructure Support Buy Rating on COMPASS Pathways’ COMP360

at www.tipranks.com (Fri, 9-Jan 5:55 AM)

Advancing COMP360 From Binary Clinical Risk to Scaled Commercial Opportunity: Buy Rating Reaffirmed on De-Risked TRD Launch and PTSD Upside

at www.tipranks.com (Thu, 8-Jan 8:45 AM)

Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

at www.tipranks.com (Thu, 8-Jan 7:18 AM)

RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

at www.tipranks.com (Thu, 8-Jan 7:16 AM)

Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)

at www.tipranks.com (Thu, 8-Jan 6:58 AM)

FDA Clears Path for Compass Pathways' Late-Stage PTSD Study—Key Milestones Signal Momentum in Mental Health Innovation

Market Chameleon (Wed, 7-Jan 8:40 AM)

Compass Pathways gets green light for late-stage study of psilocybin for PTSD

at seekingalpha.com (Wed, 7-Jan 7:50 AM)

COMPASS Pathways expands Hercules loan facility for runway

at www.tipranks.com (Wed, 7-Jan 6:57 AM)

Compass Pathways Accelerates Commercialization Plans by Up to a Year: Positive FDA Meetings and Solid Cash Reserves Highlight Q3 2025 Results

Market Chameleon (Tue, 4-Nov 11:25 AM)

CMPS Accelerates Commercial Launch Plans as Positive FDA Talks and Phase 3 Milestones Fuel Outlook

Market Chameleon (Tue, 4-Nov 7:06 AM)